The Global Urology Devices Market Will Be Worth $8.6bn by 2022  Says Visiongain Report
3 pages
English

'The Global Urology Devices Market Will Be Worth $8.6bn by 2022' Says Visiongain Report

Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres
3 pages
English
Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres

Description

'The Global Urology Devices Market Will Be Worth $8.6bn by 2022' Says Visiongain Report PR Newswire LONDON, November 5, 2012 LONDON, November 5, 2012 /PRNewswire/ -- A new report by Visiongain, a London-based business information provider, predicts that the global market for urology devices will be worth $8.6bn by 2022. The market-generated sales of $4.4bn in 2011. Similar to other markets in the medical device industry, the urology device market remained under pressure in 2011 owing primarily to increased pricing pressures. However, the market was still able to expand, with growth being fuelled by a number of factors, including patient demographics and continued advancements in minimally invasive and non-invasive surgical technologies in the urology field. The market is currently comprised of innovative urology devices for the treatment of a wide range of disorders that include urinary incontinence, prostate cancer, benign prostatic hyperplasia and kidney stones. Rodrigo Gutierrez Gamboa, healthcare industry analyst, says: "Patient demographics and a strong R&D pipeline will continue to drive growth across all segments of the urology devices market over the forecast period. There will be a sustained influx of innovative and cost-effective urology technologies in the coming years that will continue to offset economic pressures in key regional markets.

Informations

Publié par
Nombre de lectures 8
Langue English

Extrait

'The Global Urology Devices Market Will Be Worth $8.6bn by 2022' Says Visiongain Report

PR Newswire

LONDON, November 5, 2012 /PRNewswire/ --

A new report by Visiongain, a London-based business information provider, predicts that the global market for urology devices will be worth $8.6bn by 2022. The market-generated sales of $4.4bn in 2011. Similar to other markets in the medical device industry, the urology device market remained under pressure in 2011 owing primarily to increased pricing pressures. However, the market was still able to expand, with growth being fuelled by a number of factors, including patient demographics and continued advancements in minimally invasive and non-invasive surgical technologies in the urology field. The market is currently comprised of innovative urology devices for the treatment of a wide range of disorders that include urinary incontinence, prostate cancer, benign prostatic hyperplasia and kidney stones.

Rodrigo Gutierrez Gamboa, healthcare industry analyst, says: "Patient demographics and a strong R&D pipeline will continue to drive growth across all segments of the urology devices market over the forecast period. There will be a sustained influx of innovative and cost-effective urology technologies in the coming years that will continue to offset economic pressures in key regional markets. Pricing pressures have led R&D investments to be primarily focused on developing cost-effective technologies with improved safety profiles and ones that are able to streamline procedures. Over the next decade, innovation will thus be completely focused on the ability to achieve excellent clinical outcomes".
Visiongain's research also suggests that the world urology devices market may benefit from globalisation. There has been a steady rise in healthcare spending and medical insurance cover in countries such as Brazil, Russia, India and China (BRIC nations), owing to their rapidly growing economies. As a result, a greater proportion of the patient population will now be able to afford the treatments available, which will further strengthen demand in this sector.

Visiongain predicts that this market will grow steadily to 2022. The future of the urology devices market appears promising and has significant potential for growth and investment with the increasing demand for safer and cost-effective therapies. This new report adds to visiongain's wide range of analytical reports in healthcare and other industry areas.

For sample pages and further information concerning the Visiongain report Urology Devices: World Market Outlook 2012-2022 please visit http://www.visiongain.com/Report/925/Urology-Devices-World-Market-Outlook-2012-2022

For an executive summary please contact:
e-mail: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100

Companies Listed

Allengers Medical Systems
Allergan
American Medical Systems
Asahi Kasei Corporation
AstraTec
Augmenix Inc (US)
B.Braun Melsungen AG
Baxter International
Boston Scientific
C.R. Bard
Caldera Medical
Coloplast
Cook Medical
Covidien
DirexGroup
Dornier MedTech GmbH
EDAP TMS SA
Electro Medical Systems
EMK Kinetics
Endo Health Solutions
Endopharmaceutical Holdings
Ethicon
First Quality Enterprises
Fresenius Medical Care
Gen-Probe (US)
GlaxoSmithKline
Gyne Ideas
Healthtronics
Hollister
Hologic Incorporated
Hunter Urology (UK)
Intuitive Surgical
Johnson & Johnson
Karl Storz
Kimberly-Clark Corporation
Kobayashi Pharmaceutical
Laborie
Medical Service (Germany)
Medline Industries
Medtronic
Mpathy Medical Devices
Multicept (Denmark)
NeoTract (US)
Nihon Kohden
NIPRO CORPORATION
Novartis
Olympus Medical Systems Corp
Ontex International
Pfizer
ProUroCare
Richard Wolf GmbH
Storz Medical AG
Svenska Cellulosa Aktiebolaget SCA
TARIS Biomedical
Teleflex Incorporated
TENA
Uromed
Uroplasty
Varian Medical Systems
Xenolith Medical
Zynex

Notes for Editors

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

  • Univers Univers
  • Ebooks Ebooks
  • Livres audio Livres audio
  • Presse Presse
  • Podcasts Podcasts
  • BD BD
  • Documents Documents